Regenxbio (RGNX) Misses Q3 EPS by 22c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
November 5, 2019 4:05 PM ESTROCKVILLE, Md., Nov. 5, 2019 /PRNewswire/ --
Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related to certain commercial, third-party surgical devices; matter is not related to RGX-314 gene therapy candidate Positive interim update from RGX-314 Phase I/IIa trial for wet AMD presented in October at AAO Well-tolerated at all doses Anti-VEGF treatment burden was decreased by over 80% in Cohort 5,... More